DAB.bio secures funding for its commercialization phase

DAB.bio, a technology company specialized in cost-advantaged and large-scale fermentation, today announced the successful closing of an investment round led by Navus Ventures, with participation from Capricorn Partners and existing investors FORWARD.one, Innovation Quarter and Invest-NL. The investment will enable DAB.bio to build on its first commercial successes and set the stage for a series A funding round.

A Disruptive Manufacturing Technology

DAB.bio is transforming industrial biomanufacturing with its FAST™ platform technology. The patented FAST™ technology continuously removes product from the fermenter, while keeping the microbial biomass inside. The gravity-based technology is capex efficient and robust, as it does not need hard or expensive to operate membranes, centrifuges or external loops. It is therefore disruptive for manufacturing at industrial scale, and addresses the most significant impediment to large-scale biomanufacturing: product costs.

DAB.bio’s FAST™ platform enables cost-competitive manufacturing of chemicals, fuels and proteins from renewable sources. DAB.bio aims to accelerate the transition to a renewable carbon economy, whilst reducing undesired emissions and impacts from conventional production processes in the chemical and food/feed industries.

Eric van der Meer, Chief Executive Officer of DAB.bio:

• We are extremely pleased with the support from our new and existing investors. The market for industrial biotechnology is very challenging, and we regard their investment at this stage as a very strong endorsement of the quality of the team and the potential of our products. We have a strong pipeline, and have demonstrated the significant cost-reducing and at times enabling effect of continuous fermentation with FASTTM. With this funding we can deliver our first full-scale commercial deployment, and pave the way to becoming a large, European biotechnology company with a global customer base.”

Fuelling Commercial Expansion

The funding will support DAB.bio in delivering its unique FAST™ platform technology to a growing number of partners, boosting their production at large-scale fermentation processes.

Olivier van Holthe tot Echten, Investment Associate of Navus Ventures:

• The FAST™ platform of DAB.bio is a breakthrough in continuous fermentation, enabling cost-effective production of sustainable chemicals and food/feed ingredients, which fits very well into our investment strategy. We’re excited about this addition to our portfolio and to back the team as they enter their next phase of commercial growth.”

Daniela Arruda Costa, Investment Associate of Capricorn Partners:

• We are very pleased to support DAB.bio with the mission to enable a biobased transition by lowering the costs of continuous fermentation at scale. DAB.bio aligns perfectly with the vision of Capricorn Industrial Biotech Fund to invest in ventures building a sustainable society.”